The DEA Wants To Increase Marijuana and Psychedelics Production For Research Next Year



The Drug Enforcement Administration is proposing a massive increase in legal production of marijuana and psychedelics like psilocybin, LSD, MDMA, DMT and mescaline to be used in research next year. That’s on top of a big boost already made in 2021 for cannabis and psilocybin.

A new study authored by a researcher with the U.S. Department of Agriculture finds that medical marijuana laws “result in significant reductions in both violent and property crime rates, with larger effects in Mexican border states.” The federal official’s research also finds that existing studies of cannabis legalization’s impact have methodological errors that lead to “underestimation of crime reduction from ending marijuana prohibition.”

Ohio Democratic gubernatorial candidate John Cranley, currently Cincinnati’s mayor, tweeted, “🍁 Legalize marijuana 💰 Invest the tax revenue back into our communities 🚧 Create 30,000 new jobs a year that pay at least $60k ⚡ Give Ohioans a cut of our energy profits” Separately, the House speaker said he’s skeptical of a new Republican-led bill to legalize marijuana.

Michigan’s attorney general participated in an event to help people expunge marijuana and other records.

The Wisconsin Senate Judiciary and Public Safety Committee approved a bill to increase penalties for marijuana extracts.

Connecticut regulators added Huntington’s disease as a medical cannabis qualifying condition but rejected anorexia nervosa.

Oklahoma regulators issued an advisory about medical cannabis products that contain THC analogs, including THC-O-acetate.

Alabama regulators indicated that medical cannabis will not be available to patients until 2023.

Maryland regulators advanced a proposal to allow medical cannabis discounts for veterans and Medicaid recipients.

Florida regulators repealed rules on medical cannabis regulation development.

A UK man was sentenced to 25 years in prison in Dubai for possessing CBD vape oil.

A study found that “cannabis use was associated with lower risks of overweight and obesity in patients with [chronic hepatitis B virus] infection.”

source